BMJ1d
FRI0115 Humira® (Adalimumab): Fifteen Years of Controlled Production and Consistency of Quality Attributes
Background Biologics, in particular monoclonal antibodies (mAbs), transformed treatment of autoimmune diseases such as rheumatoid arthritis (RA) by selectively targeting pathogenesis and modifying ...
BMJ2d
HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?
Academic Medical Centre, University of Amsterdam, Department of Medical Microbiology, the Netherlands Dr J H Ringrose, Department of Medical Microbiology, Academic Medical Centre, AMC L1–160, PO Box ...
BMJ2d
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and ...
BMJ3d
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...
BMJ3d
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
7 National Referral Centre for Rare Systemic Auto-immune Diseases, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France Objectives To evaluate the effect of adding a 10-week treatment of ...
BMJ3d
Baseline predictors of different types of treatment success in rheumatoid arthritis
Objective To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures. Methods We used data from three rheumatoid arthritis (RA) ...
BMJ6d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...
BMJ7d
Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology
The Parker Institute, Frederiksberg Hospital, Copenhagen University Hospital, The Capital Region of Denmark, DK-2000 Copenhagen F, Denmark Søren Torp-Pedersen, The Parker Institute, Frederiksberg ...
BMJ10d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ11d
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
A substantial and persuasive body of data now exists that supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, ...
BMJ11d
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis
Objectives Myositis is a heterogeneous family of diseases that includes dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotising myopathy (IMNM), inclusion body myositis (IBM), ...
BMJ12d
L-arginine metabolism inhibits arthritis and inflammatory bone loss
Objectives To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss. Methods L-arginine was applied to three arthritis models (collagen-induced arthritis ...